Document is current
Any future updates will be listed below
-
Authors
,
Walling, A. M.
Ahluwalia, S. C.
Wenger, N. S.
Booth, M.
Roth, C. P.
Lorenz, K.
Kanwal, F.
Dy, S.
Asch, S. M.
-
Funding
Funding for this research was provided by:
Quality Enhancement Research Initiative
National Center for Advancing Translational Sciences (UL1TR000124)
NIH Loan Repayment Program
- License Information
-
More Information
Article History
Received: 19 October 2015
Accepted: 3 October 2016
First Online: 1 November 2016
Compliance with ethical standards
:
: For Drs Walling, Ahluwalia, Wenger, Booth, Dy and Asch there are no conflicts to disclose. Carol Roth has Johnson and Johnson stock. Dr. Lorenz is serving as a consultant to Otsuka Pharmaceuticals for data monitoring and safety in the evaluation of a Phase II trial of Sativex, a novel cannabinoid analgesic.
